131 related articles for article (PubMed ID: 35319502)
1. Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs.
Chanfreau-Coffinier C; Tuteja S; Hull LE; MacDonald S; Efimova O; Bates J; Voora D; Oslin DW; DuVall SL; Lynch JA
Pain; 2022 Dec; 163(12):2390-2397. PubMed ID: 35319502
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
3. Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.
Fulton CR; Zang Y; Desta Z; Rosenman MB; Holmes AM; Decker BS; Zhang Y; T Callaghan J; Pratt VM; Levy KD; Gufford BT; Dexter PR; Skaar TC; Eadon MT
Pharmacogenomics; 2019 Apr; 20(6):397-408. PubMed ID: 30784356
[No Abstract] [Full Text] [Related]
4. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
5. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids.
Knisely MR; Carpenter JS; Draucker CB; Skaar T; Broome ME; Holmes AM; Von Ah D
Appl Nurs Res; 2017 Dec; 38():107-110. PubMed ID: 29241501
[TBL] [Abstract][Full Text] [Related]
7. Use of pharmacogenetic data to guide individualized opioid prescribing after surgery.
Rocco R; Thiels CA; Ubl DS; Moyer AM; Habermann EB; Cassivi SD
Surgery; 2019 Oct; 166(4):476-482. PubMed ID: 31320226
[TBL] [Abstract][Full Text] [Related]
8. Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.
Cavallari LH; Cicali E; Wiisanen K; Fillingim RB; Chakraborty H; Myers RA; Blake KV; Asiyanbola B; Baye JF; Bronson WH; Cook KJ; Elwood EN; Gray CF; Gong Y; Hines L; Kannry J; Kucher N; Lynch S; Nguyen KA; Obeng AO; Pratt VM; Prieto HA; Ramos M; Sadeghpour A; Singh R; Rosenman M; Starostik P; Thomas CD; Tillman E; Dexter PR; Horowitz CR; Orlando LA; Peterson JF; Skaar TC; Van Driest SL; Volpi S; Voora D; Parvataneni HK; Johnson JA;
Clin Transl Sci; 2022 Oct; 15(10):2479-2492. PubMed ID: 35899435
[TBL] [Abstract][Full Text] [Related]
9. Use of CYP2D6 substrates and inhibitors during pain management with analgesic opioids: Drug-drug interactions that lead to lack of analgesic effectiveness.
Muriel J; Escorial M; Carratalá C; Margarit C; Barrachina J; López A; Gallardo E; Kringen MK; Peiró AM
Biomed Pharmacother; 2024 Jul; 176():116882. PubMed ID: 38876046
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Smith DM; Weitzel KW; Elsey AR; Langaee T; Gong Y; Wake DT; Duong BQ; Hagen M; Harle CA; Mercado E; Nagoshi Y; Newsom K; Wright A; Rosenberg EI; Starostik P; Clare-Salzler MJ; Schmidt SO; Fillingim RB; Johnson JA; Cavallari LH
Genet Med; 2019 Aug; 21(8):1842-1850. PubMed ID: 30670877
[TBL] [Abstract][Full Text] [Related]
11.
St Sauver JL; Olson JE; Roger VL; Nicholson WT; Black JL; Takahashi PY; Caraballo PJ; Bell EJ; Jacobson DJ; Larson NB; Bielinski SJ
Pharmgenomics Pers Med; 2017; 10():217-227. PubMed ID: 28769582
[TBL] [Abstract][Full Text] [Related]
12. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
13. Reviewing pharmacogenetics to advance precision medicine for opioids.
Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
[TBL] [Abstract][Full Text] [Related]
14. Chronic Pain Management in a CYP2D6 Poor Metabolizer: A Case Report for Oxycodone.
Pednekar D; Russell J; Bardolia C; Thacker D; Amin NS
Sr Care Pharm; 2024 Apr; 39(4):137-142. PubMed ID: 38528335
[TBL] [Abstract][Full Text] [Related]
15. Impact of hydrocodone reclassification on analgesic prescribing in the Veterans Health Administration.
Steckler TJ; Mosher HJ; Desloover-Koch Y; Lund BC
Am J Health Syst Pharm; 2019 May; 76(Supplement_2):S61-S67. PubMed ID: 30873558
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice.
Carranza-Leon D; Dickson AL; Gaedigk A; Stein CM; Chung CP
Pharmacogenomics J; 2021 Aug; 21(4):484-490. PubMed ID: 33750887
[TBL] [Abstract][Full Text] [Related]
17. Patterns and correlates of prescription opioid use in OEF/OIF veterans with chronic noncancer pain.
Macey TA; Morasco BJ; Duckart JP; Dobscha SK
Pain Med; 2011 Oct; 12(10):1502-9. PubMed ID: 21899715
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
[TBL] [Abstract][Full Text] [Related]
19. Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology.
Glaser GE; Maddy B; Kumar A; Ishitani K; Lemens MA; Hanson K; Moyer AM; Habermann E; Dowdy SC
Gynecol Oncol; 2024 Apr; 183():9-14. PubMed ID: 38479169
[TBL] [Abstract][Full Text] [Related]
20. Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs.
Michaud V; Bikmetov R; Smith MK; Dow P; Darakjian LI; Deodhar M; Cicali B; Bain KT; Turgeon J
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
